Foreign Pharmas Vow To Fight Korean Profit-Taking Bill
This article was originally published in PharmAsia News
Foreign pharma firms are stepping up their efforts to curb an “unprecedented” bill that would enable the South Korean government to collect what it considers unfair profits taken by original drug makers under a newly implemented drug patent-approval linkage system.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.